Severe chronic plaque psoriasis paediatric - adalimumab or ustekinumab - continuing authority application form (PB319)

Use this form to apply to continue PBS-subsidised treatment with adalimumab or ustekinumab for patients under 18 years with severe chronic plaque psoriasis.

Page last updated: 1 September 2025.
QC 55531